Scarica l'app Stockscreener
0.1588
10.33%
-0.0183
Dopo l'orario di chiusura:
.15
-0.0088
-5.54%
Scienture Holdings Inc Borsa (SCNX) Ultime notizie
Top Premarket Decliners - marketscreener.com
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened - Benzinga
Scienture Holdings Announces Reverse Stock Split - TradingView
These stocks are moving in today's after hours session - ChartMill
Scienture Holdings to implement 1-for-25 reverse stock split - Investing.com
Scienture Holdings, Inc. Announces Reverse Stock Split - The Manila Times
Operating income of Scienture Holdings, Inc. – HAN:4E4 - TradingView
Scienture Holdings, Inc. Statistics – HAN:4E4 - TradingView
Basic earnings per share (basic EPS) of Scienture Holdings, Inc. – HAN:4E4 - TradingView
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
SCNX Looks 12.9% Overvalued on GF Value™ - GuruFocus
Premarket Movers: Gainers and Losers for Sept. 22, 2026 - ChartMill
Scienture secures distribution deal for naloxone nasal spray - Investing.com
A nasal spray for opioid overdoses is headed to 2,000 clinics - Stock Titan
Scienture Holdings Inc. (SCNX) Q2 2026 Earnings: EPS Loss Narrower Than Estimated Despite Absence of Reported RevenueDebt Analysis Report - careplusvn.com
SCNX Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, but Shares SlipEarnings Momentum Score - careplusvn.com
Scienture Holdings (NASDAQ: SCNX) Releases Updated Investor Presentation for Upcoming Analyst Meetings - Kalkine Media
Scienture Holdings Updates Investor Presentation and Guidance - The Globe and Mail
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline momentum - TradingView
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline expansion - TradingView
Scienture Holdings at H.C. Wainwright: growth through niche drugs By Investing.com - Investing.com UK
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - marketscreener.com
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture (SCNX) CFO shows no personal stake in company stock - stocktitan.net
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
SCNX Q2 2026 Earnings: Loss Narrower Than Expected as EPS Beats Estimates by 70.16%ROA Comparison - dars.gov.et
SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report - dars.gov.et
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance - The Manila Times
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Scienture Holdings Inc (SCNX) Stock News Today - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 64.35%Estimate Revision Count - dars.gov.et
Scienture Holdings (SCNX) Holds Near $0.38 as Trading Range Tightens Between $0.36 Support and $0.40 ResistanceComposite Profile - dars.gov.et
Scienture Holdings, Inc. (NASDAQ: SCNX) Stock Price, News & Analysis - kalkine.ca
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, But Shares Slide 4%One-Time Gain Impact - careplusvn.com
Scienture Holdings, Inc. Revenue Breakdown – NASDAQ:SCNX - TradingView
Scienture Holdings Inc (SCNX) Cash Flow - TradingKey
6.52%
2.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):